m+Medelevator.RU
← Поиск публикаций
Journal of cardiac failure · 2015

Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Fang James C, Ewald Gregory A, Allen Larry A, Butler Javed, Westlake Canary Cheryl A, Colvin-Adams Monica, Dickinson Michael G, Levy Phillip, Stough Wendy Gattis, Sweitzer Nancy K, Teerlink John R, Whellan David J, Albert Nancy M, Krishnamani Rajan, Rich Michael W, Walsh Mary N, Bonnell Mark R, Carson Peter E, Chan Michael C, Dries Daniel L, Hernandez Adrian F, Hershberger Ray E, Katz Stuart D, Moore Stephanie, Rodgers Jo E, Rogers Joseph G, Vest Amanda R, Givertz Michael M, Heart Failure Society of America Guidelines Committee

Аннотация

We propose that stage D advanced heart failure be defined as the presence of progressive and/or persistent severe signs and symptoms of heart failure despite optimized medical, surgical, and device therapy. Importantly, the progressive decline should be primarily driven by the heart failure syndrome. Formally defining advanced heart failure and specifying when medical and device therapies have failed is challenging, but signs and symptoms, hemodynamics, exercise testing, biomarkers, and risk prediction models are useful in this process. Identification of patients in stage D is a clinically important task because treatments are inherently limited, morbidity is typically progressive, and survival is often short. Age, frailty, and psychosocial issues affect both outcomes and selection of therapy for stage D patients. Heart transplant and mechanical circulatory support devices are potential treatment options in select patients. In addition to considering indications, contraindications, clinical status, and comorbidities, treatment selection for stage D patients involves incorporating the patient's wishes for survival versus quality of life, and palliative and hospice care should be integrated into care plans. More research is needed to determine optimal strategies for patient selection and medical decision making, with the ultimate goal of improving clinical and patient centered outcomes in patients with stage D heart failure.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты